Lion Biotechnologies, Inc. (NASDAQ:IOVA) has received an average rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $13.40.

A number of research analysts have issued reports on IOVA shares. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Lion Biotechnologies in a report on Thursday, August 31st. Oppenheimer Holdings, Inc. assumed coverage on Lion Biotechnologies in a report on Friday, August 4th. They set an “outperform” rating and a $13.00 price objective for the company. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a research note on Tuesday, June 6th. Jefferies Group LLC restated a “buy” rating and issued a $11.00 target price on shares of Lion Biotechnologies in a research note on Tuesday, September 5th. Finally, Zacks Investment Research lowered Lion Biotechnologies from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd.

A number of hedge funds have recently made changes to their positions in IOVA. Franklin Resources Inc. acquired a new stake in Lion Biotechnologies in the second quarter worth about $37,844,000. FMR LLC acquired a new stake in Lion Biotechnologies in the second quarter worth about $20,833,000. Victory Capital Management Inc. acquired a new stake in Lion Biotechnologies in the second quarter worth about $19,013,000. Broadfin Capital LLC acquired a new stake in Lion Biotechnologies in the second quarter worth about $16,731,000. Finally, Vanguard Group Inc. acquired a new stake in Lion Biotechnologies in the second quarter worth about $16,113,000. Hedge funds and other institutional investors own 76.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Lion Biotechnologies, Inc. (IOVA) Given Average Recommendation of “Buy” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/24/lion-biotechnologies-inc-iova-given-average-recommendation-of-buy-by-brokerages.html.

Lion Biotechnologies (IOVA) opened at 7.70 on Friday. Lion Biotechnologies has a 12 month low of $4.45 and a 12 month high of $8.61. The company has a 50-day moving average of $5.61 and a 200-day moving average of $6.42. The company’s market cap is $482.69 million.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.